紫杉醇联合顺铂同步放疗对食管癌患者相关指标的影响  

Effect of paclitaxel plus cisplatin concurrent radiotherapy on related indicators in patients with esophageal cancer

作　　者：张森[1] 王旸[1] 杨峥[1] 余杰[1] 华松 ZHANG Sen;WANG Yang;YANG Zheng;YU Jie;HUA Song(Department of Radiotherapy,Nanyang Hospital Affiliated to Zhengzhou University,Department of Radiotherapy,Nanyang City Central Hospital,Nanyang473009,China)

机构地区：[1]郑州大学附属南阳医院放疗科南阳市中心医院放疗科,南阳473009

出　　处：《西北药学杂志》2019年第3期397-400,共4页Northwest Pharmaceutical Journal

摘　　要：目的研究紫杉醇联合顺铂同步放疗对食管癌患者免疫功能及血清肿瘤标志物水平的影响。方法选取我院收治的98例食管癌患者,随机均分为观察组和对照组。对照组实施顺铂联合放疗,观察组采用紫杉醇联合顺铂同步放疗。观察2组患者的临床疗效和不良反应,比较2组治疗前后的免疫功能指标和血清肿瘤标志物水平,并对患者进行随访观察2年,记录2组的肿瘤复发率和死亡率。结果治疗后,观察组的总有效率(79.59%)高于对照组(59.18%)(P<0.05);2组CD3+、CD4+细胞阳性率和CD4+/CD8+比值均低于治疗前,但观察组高于对照组(P<0.05);2组CD8+细胞阳性率高于治疗前,但观察组低于对照组(P<0.05);2组角蛋白19片段抗原21-1(CYFRA21-1)和鳞状上皮细胞癌抗原(SCC-Ag)均低于治疗前,且观察组低于对照组(P<0.05)。观察组不良反应发生率为18.37%,与对照组(10.20%)比较差异无统计学意义(P>0.05)。观察组患者的肿瘤复发率和患者死亡率均低于对照组(P<0.05)。结论采用紫杉醇联合顺铂同步放疗对食管癌患者疗效确切,可降低肿瘤复发率、死亡率及CYFRA21-1、SCC-Ag水平,对免疫功能有改善作用,治疗安全性好。Objective To study the effect of radiotherapy combined with paclitaxel plus cisplatin chemotherapy on immune function and serum tumor marker level in patients with esophageal cancer. Methods 98 cases of esophageal cancer admitted to our hospital were selected.They were randomly divided into observation group and control group.The control group was treated with cisplatin combined with radiotherapy,while the observation group was treated with radiotherapy combined with paclitaxel/cisplatin chemotherapy.The clinical efficacy and adverse reactions of the 2 groups were observed ,the immune function indexes and serum tumor markers before and after treatment in the 2 groups were compared,the patients were followed up for 2 years,and the recurrence rate and mortality rate of the 2 groups were recorded. Results The total effective rate of the observation group was 79.59% after treatment,which was higher than 59.18% of the control group ( P <0.05).The positive rate of CD3+ and CD4+ cells and the ratio of CD4+/CD8+ between the 2 groups after treatment were lower than those before treatment,but the observation group was higher than that of the control group ( P <0.05),the positive rate of CD8+ cells between the 2 groups after treatment was higher than that before treatment,but the observation group was lower than that of the control group ( P <0.05).The keratin19 fragment antigen 21-1 (CYFRA21-1) and squamous cell carcinoma antigen (SCC-Ag) between the 2 groups after treatment were all lower than those before treatment,and the observation group was lower than that in the control group ( P <0.05).The incidence of adverse reactions in the observation group was18.37%,and there was no significant difference compared with10.20% in the control group ( P >0.05).The rate of tumor recurrence and mortality of the patients in the observation group were lower than that of the control group( P <0.05). Conclusion Radiotherapy combined with paclitaxel plus cisplatin chemotherapy is effective in treating esophageal cancer, which can reduce

关 键 词：紫杉醇 顺铂 食管癌 免疫功能 肿瘤标志物 

分 类 号：R979.1[医药卫生—药品]